首页 > 文献资料
-
Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that recurs while a patient is receiving androgen deprivation therapy (ADT). Many treatment options have been suggested for this chal enging disease;starting from 2-year hormonal manipulations, mitoxantrne-and docetaxel-based regimens reaching to the overwhelming new systemic op-tions for CRPC (newer hormonal treatments, cytotoxic chemotherapies, bone-targeted agents and immunotherapeutics);and the question is:do the traditional cytotoxic regimens stil have a role amidst al these new options?